Company
Brian Tiplady, Ph.D.
– Senior Scientific Consultant 
Dr. Tiplady was trained as a Neuroscientist, working first in academic research, then with the Swedish pharmaceutical company Astra (later part of AstraZeneca). He was responsible for projects in central nervous system clinical research, first in depression, and then in senile dementia. In Dr. Tiplady’s 27 years in the pharmaceutical industry, he has been involved with all stages of the clinical trial process, from being an investigator in human pharmacology studies, through monitoring, project management, data handling and IT, statistical analysis and reporting. Starting in 1993, he became increasingly involved with electronic diaries and questionnaires, having set up some of the early evaluation studies which showed high patient acceptability of these systems. He supported a variety of in-house projects at AstraZeneca using handheld diaries, and worked with strategic and logistic issues involved in effectively using electronic data collection of patient reported outcomes, and in evaluating the benefits obtained.
Where to find Brian:
22 June 2008 - DIA Annual Meeting; Boston, MA
Dr. Brian Tiplady will present “Electronic Patient Diaries: Validation in an Unsupervised Setting” For more information, visit www.diahome.org
20 July 2008 - British association for Psychopharmacology Annual Meeting; Harrogate, UK
Dr. Tiplady will present, "Improving the quality of self-assessment instruments in psychopharmacological research" - For more information, visit www.BAP.org.uk
Webinar Replay: Practical Implications of the FDA Draft PRO Guidance
Dr. Tiplady discussed life after the FDA’s Draft PRO Guidance, including Meaning of “Conceptual Framework” as defined by the FDA; Best practices in defining a solid endpoint model; Necessary steps to determine the validity of a PRO measure; and, Practical steps to migrate from paper to electronic patient reported outcomes (PROs). - View webinar today!